Full-Time

Development Associate

Antibody Content

Confirmed live in the last 24 hours

Nomic

Nomic

51-200 employees

Develops advanced proteomics solutions using nanotechnology

No salary listed

Mid

Montreal, QC, Canada

The majority of the team is based in Montreal and works in a new, shared office/laboratory space with an in-person, but flexible work-from-home, policy.

Category
Bioinformatics
Biology Lab & Research
Biology & Biotech
Required Skills
Data Analysis
Requirements
  • Bachelors or Masters in a Biology-related field or equivalent, with a minimum of 3 years of wet lab experience and experience in the BioTech Industry (min 1 year exp w/ Masters, 2-3 years exp w/ Bachelors)
  • Knowledge of techniques in a biotechnology discipline, e.g. ELISA, flow cytometry, bead-based assays, bio-conjugation & purification, spectroscopy, microscopy, PCR, cell culture
  • For internal candidates, experience with UMC and/or UPC workflows
  • Able to work independently and as part of a team in a fast-paced environment
  • Data driven, strong analytical and problem-solving skills with attention to detail
  • Able to manage projects and facilitate cross-functional efforts.
Responsibilities
  • Contribute to our content expansion and performance improvements by sourcing antibodies, running screening and expansion manufacturing protocols and validation assays
  • Lead and contribute to the development of new content within our growing plex list. Requires working with various robotics (Lynx) and other instruments for manufacturing and testing
  • Troubleshoot potential issues that may arise during the development and testing of new targets, whether autonomously or in cross-functional initiative
  • Contribute to building the content launch operating unit by developing and deploying new features, protocols and workflows in collaboration with the manufacturing, automation, software and Data teams to accommodate plex expansion
  • Research and investigate antibodies and antigens within the industry to find content that is likely to have the best success in our nELISA platform technology
  • Use project management skills (along with accurate record keeping and documentation) to keep track of the progress of multiple targets in various stages of development from procurement to launch.
Desired Qualifications
  • Connect deeply with our mission, ambition and sense of duty
  • Are up for a challenge and want to grow
  • Want to be at the cutting-edge of biotechnology
  • Love hands-on lab work, and want to take hold of key learnings from experiments, and use them to develop improved analytical methods to ensure the robust biological validation of immunoassays
  • Prefer working and communicating within a diverse cross-functional team.

Nplex Biosciences develops advanced solutions for protein measurement in the biotechnology sector, focusing on proteomics using nanotechnology. Their main product, the nELISA, is a compact and efficient version of the traditional sandwich ELISA immunoassay, allowing for the simultaneous analysis of multiple proteins in a cost-effective manner. This platform addresses previous economic challenges in antibody-based proteomics, making it accessible for various research teams in academic institutions, pharmaceutical companies, and biotech firms. Nplex Biosciences differentiates itself by utilizing DNA nanotechnology to accurately identify proteins on tiny beads, which enhances the precision and efficiency of protein analysis. The company's goal is to provide a scalable and reliable proteomics platform that supports high-throughput needs in drug discovery, biomarker discovery, and personalized medicine.

Company Size

51-200

Company Stage

Series B

Total Funding

$60M

Headquarters

Montreal, Canada

Founded

2017

Simplify Jobs

Simplify's Take

What believers are saying

  • Nomic secured $42M in Series B funding to expand protein profiling capabilities.
  • The rise of personalized medicine increases demand for high-throughput proteomics solutions.
  • Global proteomics market projected to grow at 14.1% CAGR from 2023 to 2028.

What critics are saying

  • Emerging competition from SomaLogic and Olink may impact Nomic's market share.
  • Rapid technological advancements could render Nomic's platform obsolete without continuous innovation.
  • Supply chain vulnerabilities in nanotechnology components could disrupt production schedules.

What makes Nomic unique

  • Nomic's nELISA platform offers scalable, cost-effective protein measurement solutions.
  • The company leverages DNA nanotechnology for precise protein analysis on micron-sized beads.
  • Nomic serves high-throughput needs in drug discovery and personalized medicine sectors.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Flexible Work Hours

Growth & Insights and Company News

Headcount

6 month growth

8%

1 year growth

0%

2 year growth

1%
Yahoo Finance
Sep 19th, 2024
Nomic® Secures $42M in Oversubscribed Series B to Expand Access to Protein Profiling

MONTREAL, September 17, 2024--Nomic Bio ("Nomic"), the Protein Profiling company, today announces the completion of an oversubscribed $42 million Series B funding round. The fresh capital will enable Nomic to accelerate the expansion of its commercial operations, further invest in advancing its state-of-the-art protein profiling platform, and broaden its transformative offerings to meet growing demand.

BetaKit
Mar 18th, 2020
11 Canadian companies in Y Combinator’s Winter 2020 Demo Day

This week, Y Combinator (YC) held its Winter 2020 Demo Day, the 30th for the Silicon Valley incubator. To minimize health concerns during the COVID-19 outbreak, YC opted to host the demo day online. For this cohort, 16 Canadian startups participated.

TechCrunch
Mar 17th, 2020
All the companies from Y Combinator’s W20 Demo Day, Part IV: Healthcare, Biotech, Fintech and Nonprofits

Y Combinator’s Demo Day was a bit different this time around.